Aktiesnakken — Oktober 2010
-
hahaha
-
nu vil jeg ikke fremhæve at jeg hele tiden sagde at man skulle afvente salgstal
-
jeg vidste godt at de kunne skuffe nogen, der ikke har siddet med snuden i uptake grafer, men nu ligger triggerne på rad og række i genmab
-
vi har mulig: deal på fabrik, deal på zalu, deal på cd38, opjusering ved regnskab
-
jeg mener helt sikkert at David kan guide mod 50-60 mill i omsætning på arzerra
-
Noget bud på overtagelseskurs af H+H?
-
70-80 stocky
-
HRmunk - tak - er du selv gået ind?
-
Aka - er du i H+H?
-
OK
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind